scholarly journals A new enzyme-linked immunosorbent assay system for human serum hepatic triglyceride lipase

2017 ◽  
Vol 58 (8) ◽  
pp. 1591-1597 ◽  
Author(s):  
Kazuya Miyashita ◽  
Katsuyuki Nakajima ◽  
Isamu Fukamachi ◽  
Yuji Muraba ◽  
Takafumi Koga ◽  
...  
Keyword(s):  
Human Serum ◽  
Immunosorbent Assay ◽  
Assay System ◽  
Enzyme Linked Immunosorbent Assay ◽  
Hepatic Triglyceride ◽  
Triglyceride Lipase ◽  
Hepatic Triglyceride Lipase

scholarly journals A new enzyme-linked immunosorbent assay system for human hepatic triglyceride lipase

2013 ◽  
Vol 424 ◽  
pp. 201-206 ◽  
Author(s):  
Kazuya Miyashita ◽  
Junji Kobayashi ◽  
Shigeyuki Imamura ◽  
Noriaki Kinoshita ◽  
Kimber L Stanhope ◽  
...  
Keyword(s):  
Immunosorbent Assay ◽  
Assay System ◽  
Enzyme Linked Immunosorbent Assay ◽  
Hepatic Triglyceride ◽  
Triglyceride Lipase ◽  
Hepatic Triglyceride Lipase

Selective Deficiency of Hepatic Triglyceride Lipase in Uremic Patients

1977 ◽  
Vol 297 (25) ◽  
pp. 1362-1366 ◽  
Author(s):  
Rubino Mordasini ◽  
Felix Frey ◽  
Walter Flury ◽  
Gerald Klose ◽  
Heiner Greten
Keyword(s):  
Hepatic Triglyceride ◽  
Triglyceride Lipase ◽  
Uremic Patients ◽  
Hepatic Triglyceride Lipase

Microfluidic tectonics platform: A colorimetric, disposable botulinum toxin enzyme-linked immunosorbent assay system

2004 ◽  
Vol 25 (1011) ◽  
pp. 1705-1713 ◽  
Author(s):  
Jaisree Moorthy ◽  
Glennys A. Mensing ◽  
Dongshin Kim ◽  
Swomitra Mohanty ◽  
David T. Eddington ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Immunosorbent Assay ◽  
Assay System ◽  
Enzyme Linked Immunosorbent Assay

scholarly journals Development and Validation of 13-plex Luminex-Based Assay for Measuring Human Serum Antibodies to Streptococcus pneumoniae Capsular Polysaccharides

mSphere ◽  
2018 ◽  
Vol 3 (4) ◽  
pp. e00128-18 ◽  
Author(s):  
Danka Pavliakova ◽  
Peter C. Giardina ◽  
Soraya Moghazeh ◽  
Shite Sebastian ◽  
Maya Koster ◽  
...  
Keyword(s):  
Human Serum ◽  
Lower Limit ◽  
Immunosorbent Assay ◽  
Enzyme Linked Immunosorbent Assay ◽  
Igg Antibodies ◽  
Igg Antibody ◽  
Correlate Of Protection ◽  
Immune Correlate ◽  
Relative Standard ◽  
Limit Of Quantitation

ABSTRACT A Luminex-based direct immunoassay (dLIA) platform has been developed to replace the standardized pneumococcal enzyme-linked immunosorbent assay platform. The multiplex dLIA simultaneously measures the concentration of serum immunoglobulin G (IgG) antibodies specific for pneumococcal capsular polysaccharide (PnPS) serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. The assay uses poly-l-lysine (PLL)-conjugated PnPS, chemically coupled to spectrally distinct Luminex microspheres. Assay validation experiments were performed using residual human serum samples obtained from 13-valent pneumococcal conjugate vaccine (13vPnC) clinical studies. Assay results are expressed as IgG antibody concentrations in micrograms per milliliter using the international reference serum, 007sp. The lower limit of quantitation (LLOQ) for all serotypes covered in the 13-plex dLIA fell within the range of 0.002 to 0.038 µg/ml serum IgG. The difference between the lower limit and upper limit of the assay range was >500-fold for all serotypes, and assay variability was <20% relative standard deviation (RSD) for all serotypes. IgG antibody measurements were shown to be serotype-specific (some cross-reactivity was observed only between the structurally related serotypes 6A and 6B as well as 19A and 19F), and no interference was observed between the serotypes when the assay was performed in the 13-plex format compared to the singleplex assays. The 13-plex dLIA platform developed by Pfizer Inc. generates up to 143 test results in a single 96-well plate and is a suitable replacement of the enzyme-linked immunosorbent assay (ELISA) platform for evaluating vaccine clinical trials. IMPORTANCE The pneumococcal enzyme-linked immunosorbent assay (ELISA) measures IgG antibodies in human serum, and it is an important assay that supports licensure of pneumococcal vaccines. The immune correlate of protection, 0.35 µg/ml of IgG antibodies, was determined by the ELISA method. Pfizer has developed a new Luminex-based assay platform to replace the ELISA. These papers describe the important work of (i) validating the Luminex-based assay and (ii) bridging the immune correlate of protection (0.35 µg/ml IgG) to equivalent values reported by the Luminex platform.

Sign in / Sign up

Export Citation Format

Share Document